| Autor: |
Ocias LF, Holmström MO, Riley CH, Andersen CL, Rønnov-Jessen D, Starklint J, Frederiksen M, Steffensen MS, Bjerrum OW, Farmer S, Mourits-Andersen T, Hasselbalch HC; Hæmatologisk Afdeling, Roskilde -Sygehus, Køgevej 7-13, 4000 Roskilde. hans.hasselbalch@dadlnet.dk., Larsen TS |
| Jazyk: |
dánština |
| Zdroj: |
Ugeskrift for laeger [Ugeskr Laeger] 2015 May 04; Vol. 177 (19). |
| Abstrakt: |
Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
